Aritzia, a retailer known for its 'Everyday Luxury' brand, reported a 60% revenue increase in the U.S. for Q2 2027, driven by new boutiques that are outperforming expectations with payback periods under one year. Management has raised its full-year revenue growth guidance to 29-32% and expects a 20% adjusted EBITDA margin, reflecting strong operational execution and scaling benefits. Despite a premium valuation and fashion industry risks, the company shows promising growth potential, particularly in the U.S. market. The analyst remains optimistic but advises caution due to the recent stock rally.
Aritzia stock performance context is provided with data from Pluang as of Oct 29, 2026 21:02 WIB. For readers following Consumer Cyclical-sector US stocks, here is Pluang's market snapshot: out of 134 priced stocks, 111 rose and 22 fell today. Notable movers include MBLY at USD 6.59 with a 1-day change of -6.66% and a typical hold time of 16 days, FIGS at USD 21.83 up 5.66% with 100% sell order activity, and VFC at USD 18.16 up 5.40% with a typical hold time of 64 days. The highest daily gain observed among these was FIGS at +5.66%.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
